西藏奇正藏药股份有限公司 投资者关系活动记录表 证券代码：002287 证券简称：奇正藏药 债券代码：128133 债券简称：奇正转债 | 10、问：请问公司的创新药是什么药？ | | --- | | 答：您好，公司小儿热立清颗粒属于中药分类一类创新 | | 药，已于今年获得中药 1.1 类新药临床批准通知书。谢 | | 谢。 | | 11、问：公司推出的持股计划仅以营业收入增长作为考 | | 核指标，未设置利润考核门槛，这是否会导致激励与经 | | 营质量脱节？今年的收入目标能达到吗？ | | 答：您好，公司推出的员工持股计划是既考虑了营业收 | | 入的增长、又考虑到公司净利润增长要求。通过员工持 | | 股计划和长期激励基金提取的有机结合，兼顾经营规模 | | 和经营质量。公司员工持股计划的考核围绕营业收入指 | | 标，是配合本战略周期的核心策略而制定，营业收入是 | | 衡量公司经营状况和市场占有能力、预测公司经营业务 | | 拓展趋势的重要财务指标，能够直观反映公司的成长能 | | 力和行业竞争力，具体考核的设定需要考虑行业发展及 | | 市场竞争情况、公司经营状况及发展规划等相关因素， | | ...

（记者 张明双） 奇正藏药（002287.SZ）8月7日在投资者互动平台表示，公司2025年暂未推出新药。公司的新药小儿热 立清颗粒于2025年5月收到国家药品监督管理局签发的《药物临床试验批准通知书》，同意本品在儿童 人群开展用于急性上呼吸道感染风热夹湿证的临床试验。公司将依据通知书以及新药开发与药品注册法 规要求，开展Ⅱ期和Ⅲ期临床试验并完成相关工作，整合申报资料以申报产品上市。其他在研产品研发 进展情况请关注公司将于2025年8月23日发布的《2025年半年度报告》。 每经AI快讯，有投资者在投资者互动平台提问：请问贵公司，2025年推出了哪些新药，向国家药品监 督管理局申请了哪些新药？ ...

Core Viewpoint - The approval of clinical trials for the pediatric medication "Xiaoer Reliqing Granules" marks a significant advancement in the company's product development, potentially enhancing its competitiveness in the pediatric market [1][2]. Group 1: Drug Information - Drug Name: Xiaoer Reliqing Granules - Indication: Acute upper respiratory tract infections classified as wind-heat with dampness according to traditional Chinese medicine - Registration Category: Innovative Chinese Medicine Class 1.1 - Acceptance Number: CXZL2500015 - Notification Number: 2025LP01422 - The clinical trial application for Xiaoer Reliqing Granules was accepted on March 14, 2025, and meets the requirements for drug registration [1]. Group 2: Product Efficacy - Preclinical studies indicate that Xiaoer Reliqing Granules exhibit significant antipyretic effects in rabbit and rat fever models, extend cough latency, reduce cough frequency in guinea pigs, and show notable anti-inflammatory effects in acute inflammatory models [2]. - Toxicological studies suggest that the drug has good safety with a wide safety dosage range [2]. Group 3: Approval Process and Company Impact - Following the approval of the clinical trial notification, the company must conduct Phase II and III clinical trials and complete related work to prepare for product registration [2]. - The approval is a crucial step in the product's development, although the drug development process is characterized by high investment, long cycles, and significant risks, which may not have an immediate impact on the company's financial performance [2].